Skip to main content

Alzheimer’s Drug Cost Pushes Pharmaceutical Prices Back Into the Spotlight

Biogen’s (NASDAQ: BIIB) Aduhelm sparked a rally in the biotech giant’s share price and hope that progress is being made in treating Alzheimer’s. However, the news isn’t free of controversy, and carries with it implications for healthcare exchange traded funds, including the...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.